Compare Li Auto Inc (LI) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Li Auto Inc vs Neurocrine Biosciences Inc — how do they compare? Li Auto Inc trades at $11.54 (market cap $10.71B), while Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Li Auto Inc for 101 Days and Neurocrine Biosciences Inc for 23 Days on average.
| LI | NBIX | |
|---|---|---|
Market Cap | $10.71B | $14.36B |
Volume | 1,781,143 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $23.13 | $185.50 |
52-Week Low | $10.69 | $123.10 |
Typical Hold Time | 101 Days | 23 Days |
Enterprise Value | $139.58M | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Li Auto (LI) trades at $10.90, down 0.82% and near 52-week lows, reflecting bearish technical signals and recent earnings misses. The company reported declining revenue ($112.31B in 2025) and negative net income margins (-4.4%), though valuation metrics like P/S (0.73) appear attractive. Recent news highlights delivery moderation and new model launches (Li i9, Li MEGA) amid intense EV competition.
The stock faces near-term headwinds from cash burn and competitive pressures, but analyst consensus remains cautiously optimistic with a $15.18 price target. Key risks include execution challenges in global expansion and margin recovery, while potential upside hinges on successful product cycles and cost management improvements.
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
